SCHEMBL982570

SCHEMBL982570

CC(C)(C)Nc1ncccc1C(=O)Nc1cccc(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.61
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK1 P28482 1/20 0.51
KDR P35968 1/20 0.51
PABPC1 P11940 1/20 0.50
EIF4H Q15056 1/20 0.50
TOP1 P11387 1/20 0.48
DHODH Q02127 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPT P10636 2/20 0.46
PLEC Q15149 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL986395 0.88 KDR (0.49) GAAMEN1KMT2AKDRPABPC1
SCHEMBL984889 0.81 L3MBTL1 (0.48) GAAMEN1KMT2AKDRPABPC1
SCHEMBL985740 0.78 GAA (0.64) GAAMEN1KMT2AKDRPABPC1
SCHEMBL986394 0.76 L3MBTL1 (0.48) MEN1KMT2AKDRPABPC1EIF4H
SCHEMBL28331750 0.76 CYP1A2 (0.60) GAAMEN1KMT2AKDRPABPC1
SCHEMBL1425938 0.75 RAF1 (0.46) GAAMEN1KMT2AKDRSMN1; SMN2
SCHEMBL10103838 0.74 KMT2A (0.44) GAAMEN1KMT2AKDRSMN1; SMN2
SCHEMBL29217384 0.73 ALDH1A1 (0.67) GAAMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL16829204 0.72 ALDH1A1 (0.60) MEN1KMT2ADHODHSMN1; SMN2MAPT
SCHEMBL15635803 0.72 DHODH (0.58) GAAMEN1KMT2AMAPK1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232406-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-31 US disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 GAA 1570/4885MEN1 402/4885KMT2A 1014/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 GAA 1570/4885MEN1 402/4885KMT2A 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.